UMIN-CTR Clinical Trial

UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials


Recruitment status Completed
Unique ID issued by UMIN UMIN000036325
Receipt No. R000040684
Scientific Title Effects of a Test Food for Defecation Improvement.
Date of disclosure of the study information 2019/03/28
Last modified on 2019/09/17

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments

Basic information
Public title Effects of a Test Food for Defecation Improvement.
Acronym Effects of a Test Food for Defecation Improvement.
Scientific Title Effects of a Test Food for Defecation Improvement.
Scientific Title:Acronym Effects of a Test Food for Defecation Improvement.

Condition N/A(healthy adults)
Classification by specialty
Classification by malignancy Others
Genomic information NO

Narrative objectives1 This study aims to evaluate effects of a test food for defecation improvement and its safety(a randomized, double-blind, placebo-controlled, parallel-group study).
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Primary outcomes [1]Indexes for evaluating defecation (The Japanese Version of the Constipation Assessment Scale (1), Patient Assessment of Constipation of Quality Of Life scale (1), Bristol stool scale (1), bowel diary (2)).
(1):Screening, Week 0, Week 2, Week 4.
(2):From the first day of ingestion of a test material to the last day of the test.
Key secondary outcomes *Safety
[1]Blood pressure, pulsation (Screening, Week 0, Week 4).
[2]Weight, body fat percentage, BMI (Screening, Week 0, Week 4).
[3]Doctor's questions (Screening, Week 0, Week 4).
[4]Subject's diary (each day during the test period).

Study type Interventional

Study design
Basic design Parallel
Randomization Randomized
Randomization unit Individual
Blinding Double blind -all involved are blinded
Control Placebo
Dynamic allocation
Institution consideration

No. of arms 2
Purpose of intervention Treatment
Type of intervention
Interventions/Control_1 Oral intake of the test product (4 capsules in a day for 4 weeks)
Interventions/Control_2 Oral intake of the placebo product (4 capsules in a day for 4 weeks)

Age-lower limit
20 years-old <=
Age-upper limit
60 years-old >
Gender Male and Female
Key inclusion criteria [1]Healthy Japanese males and females aged 20-59 years.
[2]Individuals who are healthy and have no chronic physical disease.
[3]Individuals with a tendency for constipation (at 3-5 times of defecation per week); whose stool shape is relatively hard and who have unpleasant sensation on defecation.
[4]Individuals whose written informed consent has been obtained.
[5]Individuals who can have an examination on a designated check day.
[6]Individuals judged appropriate for the study by the principal.
Key exclusion criteria [1]Individuals using medical products.
[2]Individuals who are patient or have a history of psychiatric disease, high blood pressure, diabetes, and hyperlipidemia.
[3]Individuals whose stool frequency is less than 3 times per week.
[4]Individuals who are constipated because of intaking internal medicine.
[5]Individuals who have idiopathic constipation.
[6]Individuals whose eating habits are irregular.
[7]Individuals who used a drug to treat a disease in the past 1 month (except temporal usage for pollenosis).
[8]Individuals who have a history of serious hepatopathy, kidney damage, heart disease and hematological disease.
[9]Individuals who are a patient or have a history of or endocrine disease.
[10]Individuals whose BMI is over 30.
[11]Individuals who are sensitive to a test product or other foods, and medical products.
[12]Individuals who intake laxatives, antiflatulent etc. aiming to improve bowel movements.
[13]Individuals who excessively take alcohol (expressed in an amount of alcohol: over 60mg/day).
[14]Individuals with possible changes of life style, such as working a night shift, during the test period.
[15]Individuals who are or are possibly, or are lactating.
[16]Individuals who participated in other clinical studies in the past 3 months.
[17]Individuals who are or whose family is engaged in functional foods or cosmetics.
[18]Individuals judged inappropriate for the study by the principal.
Target sample size 60

Research contact person
Name of lead principal investigator
1st name Toshifumi
Middle name
Last name Okusa
Organization Oriental Ueno Detection Center, General Incorporated Association Oriental Occupational Health Association Tokyo Branch
Division name Head of Center
Zip code 110-0005
Address 1-20-11 Ueno Taito-ku Tokyo 110-0005, JAPAN
TEL +81-3-5816-0711

Public contact
Name of contact person
1st name Ryoma
Middle name
Last name Shimizu
Organization TES Holdings Co., Ltd.
Division name Administrative Department of Clinical Trials
Zip code 110-0015
Address 6F Kairaku Building 2-7-5 Higashiueno Taito-ku Tokyo 110-0015, JAPAN
TEL +81-3-601-8480
Homepage URL

Institute TES Holdings Co., Ltd.

Funding Source
Organization Kobayashi Pharmaceutical Co., Ltd.
Category of Funding Organization Profit organization
Nationality of Funding Organization

Other related organizations
Name of secondary funder(s)

IRB Contact (For public release)
Organization Ueno-Asagao Clinic Ethical Review Committee
Address 6F Kairaku Building 2-7-5 Higashiueno Taito-ku Tokyo 110-0015, JAPAN
Tel +81-3-6240-1162

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2


Other administrative information
Date of disclosure of the study information
2019 Year 03 Month 28 Day

Related information
URL releasing protocol
Publication of results Unpublished

URL related to results and publications
Number of participants that the trial has enrolled 60
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Recruitment status Completed
Date of protocol fixation
2019 Year 01 Month 29 Day
Date of IRB
2019 Year 01 Month 16 Day
Anticipated trial start date
2019 Year 03 Month 04 Day
Last follow-up date
2019 Year 04 Month 07 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other related information

Management information
Registered date
2019 Year 03 Month 28 Day
Last modified on
2019 Year 09 Month 17 Day

Link to view the page

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name

Contact us.